Merck receives positive CHMP opinion for KEYTRUDA® (pembrolizumab)
Merck announced that the Committee for Medicinal Products for Human Use of the EMA has adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for treatment of advanced melanoma, as both first-line therapy and in previously treated patients. May 22, 2015